Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02949388 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
A Phase 2 study, sponsored by Innovation Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT02949388 is a Phase 2 study that has completed, run by Innovation Pharmaceuticals. The registered enrollment target is 199 participants.
The verdict
NCT02949388, a Phase 2 study, has completed, sponsored by Innovation Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG 400 mg (200 mg BID)
- DRUG 300 mg (150 mg BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02949388
The ClinicalTrials.gov registry entry for NCT02949388 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innovation Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02949388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02949388 about?
NCT02949388 is a clinical study titled "Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis". This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT02949388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2016-11. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02949388?
The interventions under investigation include: Placebo (DRUG), 400 mg (200 mg BID) (DRUG), 300 mg (150 mg BID) (DRUG).
Who is sponsoring clinical trial NCT02949388?
This trial is sponsored by Innovation Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.